IRVINE, Calif.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (Nasdaq: AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced that Casey Kopczynski, Ph.D., Chief Scientific Officer, will present in a fireside chat discussion at the RBC Capital Markets 2017 Global Healthcare Conference on Wednesday, February 22, 2017 at 8:30 a.m. Eastern Time in New York, NY. Dr. Kopczynski will provide his perspective on Aerie’s lead product candidates, as well as ongoing pre-clinical activities.
The fireside chat discussion will be webcast live and may be accessed by visiting Aerie's website at http://investors.aeriepharma.com/. A replay of the webcast will be available for 10 business days.
About Aerie Pharmaceuticals, Inc.
Aerie is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie's two lead product candidates are once-daiIy IOP-lowering therapies with novel mechanisms of action to treat patients with glaucoma or ocular hypertension. The NDA filing for RhopressaTM (netarsudil ophthalmic solution) 0.02% was originally submitted in the third quarter of 2016 and is expected to be resubmitted near the end of the first quarter of 2017. The second product candidate, RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, which is a fixed dose combination of RhopressaTM and widely prescribed PGA latanoprost, currently has two Phase 3 registration trials underway, named Mercury 1 and Mercury 2. If these trials are successful, a RoclatanTM NDA filing is expected to take place near year-end 2017. Aerie is also focused on the development of additional product candidates and technologies in ophthalmology.